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Boston, Massachusetts; Toronto, Ontario, Canada; and Ann Arbor, MichiganObjectives This study sought to evaluate the clinical relevance of potential clopidogrel drug–drug
interactions.
Background Some studies have demonstrated that statins and calcium-channel blockers (CCBs) may
attenuate the pharmacodynamic effects of clopidogrel.
Methods The TRITON–TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing
Platelet Inhibition With Prasugrel–Thrombolysis in Myocardial Infarction 38) enrolled 13,608 patients
with an acute coronary syndrome (ACS) and planned percutaneous coronary intervention (PCI), and
randomized them to clopidogrel or prasugrel. Use of a statin or CCB was left to the discretion of the
treating physician. A multivariable Cox model with propensity score was employed to evaluate the
association between statin or CCB use and clinical outcomes.
Results Of the 6,795 subjects assigned to clopidogrel, 4,794 (70.6%) were on a CYP3A4-metabolized
statin, and 966 (14.2%) were on a CCB at randomization. The risk of cardiovascular (CV) death,
myocardial infarction (MI), or stroke was similar regardless of baseline use of statins (adjusted hazard
ratio [HR]: 1.02, 95% conﬁdence interval [CI]: 0.85 to 1.22) or CCBs (adjusted HR: 1.16; 95% CI: 0.94 to
1.43) in clopidogrel-treated patients. Further, the combined use of a CCB and atorvastatin 80 mg daily
(adjusted HR: 0.82; 95% CI: 0.37 to 1.84), or a CCB, statin, and proton pump inhibitor (adjusted HR: 1.04;
95% CI: 0.70 to 1.54) were not associated with an increased risk of CV death, MI, or stroke. The use of
statins or CCBs did not modify the relative efﬁcacy of prasugrel versus clopidogrel for the primary
endpoint (p for interaction ¼ 0.43, 0.55, respectively).
Conclusions In patients with ACS undergoing PCI, the use of statins or CCBs was not associated with
an increased risk of CV events in clopidogrel-treated patients. Consistent results were observed when
the drugs were administered alone, together, or in combination with proton pump inhibitors. (J Am
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1276Statins and calcium-channel blockers (CCBs) are frequently
co-administered with clopidogrel after an acute coronary
syndrome (ACS). Because clopidogrel requires hepatic me-
tabolism via the cytochrome P450 (CYP) enzyme system to
form its active metabolite, there exists concern that certain
drugs, such as statins or CCBs, that are metabolized by or
inhibit isoenzymes along this pathway, can interfere with the
clinical efﬁcacy of clopidogrel.
See page 1282
These concerns are supported by studies that have
demonstrated that atorvastatin (1–3) or CCBs (4–6) can
attenuate the pharmacodynamic effects of clopidogrel in
vitro; however, the results from pharmacodynamic studies
remain mixed (7) and the clinical implications of these
ﬁndings remain unclear. We therefore assessed whether
statins or CCBs interfere with the clinical efﬁcacy of clo-
pidogrel in a large trial population of patients with ACSthey have no relationships relevant t
TRITON–TIMI 38 trial was spon
Company. The current analysis receiv
Abbreviations
and Acronyms
ACS = acute coronary
syndrome
CCB = calcium-channel
blocker
CI = conﬁdence interval
CV = cardiovascular
HR = hazard ratio
MI = myocardial infarction
PCI = percutaneous coronary
interventionundergoing percutaneous coro-
nary intervention (PCI). Fur-
ther, we assessed the relative
efﬁcacy and safety of prasugrel
versus clopidogrel in those
subjects who were treated with
statins or CCBs.
Methods
The TRITON–TIMI 38 (Trial
to Assess Improvement in Ther-
apeutic Outcomes by Optimiz-
ing Platelet Inhibition With
Prasugrel–Thrombolysis in Myo-cardial Infarction 38) study was a double-blind, phase 3 trial
that enrolled 13,608 patients with moderate-to-high-risk
ACS undergoing planned PCI, and randomized them to
prasugrel (60-mg loading dose, 10 mg a day maintenance dose)
or clopidogrel (300-mg loading dose, 75 mg a day maintenance
dose) for a median duration of 14.5 months (8). The primary
endpoint of the TRITON–TIMI 38 trial was the composite of
cardiovascular (CV) death, nonfatal myocardial infarction
(MI), or nonfatal stroke. Relevant exclusions to participation
in the trial included an increased risk of bleeding, a history
of anemia, thrombocytopenia, or pathological intracranial
ﬁndings.
Statin or CCB use. The decision to treat with a statin or
CCB was left to the discretion of the treating physician. The
names (brand name or generic), doses, and start and stopo the contents of this paper to disclose. The
sored by Daiichi Sankyo and Eli Lilly and
ed no sources of external funding. The TIMIdates of concomitant medications were captured on the case
report forms at patient visits. For the current analysis, we
deﬁned statin use as all statins that were known to be
metabolized by the CYP3A4 enzyme system, including
atorvastatin, simvastatin, cerivastatin, and lovastatin. On
the basis of prior pharmacodynamic studies (1–3), we
also examined atorvastatin use individually in a sensitivity
analysis. CCB use was deﬁned as any of the following
subtypes that are metabolized by or inhibit the CYP3A4
isoenzyme, including diltiazem, verapamil, nifedipine, felo-
dipine, amlodipine, nisoldipine, isradipine, nimodipine,
nicardipine, lercanidipine, nitrendipine, bepridil, lacidipine,
barnidipine, and azelnidipine.
All primary efﬁcacy and key safety endpoints were adju-
dicated by an independent clinical events committee who
were unaware of the assigned treatment; however, the use of
concomitant medications including CCBs and statins was
not concealed. For the current analysis, stent thrombosis was
deﬁned according to the Academic Research Consortium
(ARC) deﬁnite or probable deﬁnitions (9).
Statistical analysis. Baseline characteristics are presented as
medians (interquartile ranges) for continuous variables and
frequencies for categorical variables. Comparisons for base-
line characteristics were made with Wilcoxon rank sum tests
for continuous variables and chi-square tests for categorical
variables.
Multivariable Cox proportional hazards model was used
to examine the independent association between use of
a statin and/or CCB and the risk of adverse outcomes for
patients on clopidogrel. Using logistic regression modeling
with a forward selection algorithm (p for inclusion < 0.20),
propensity scores were developed to account for the clini-
cian’s decision to treat with a statin or CCB. The ﬁnal
variables included in each propensity score and multivariable
models are included in the Online Appendix. Because
patients could start or stop medications during the course of
study, we conducted sensitivity analyses that were restricted to
those subjects on a concomitant medication of interest both at
randomization and at the end of the study.
All efﬁcacy analyses comparing prasugrel with clopidogrel
were conducted according to the intention-to-treat prin-
ciple. Rates of endpoints are expressed as Kaplan-Meier
estimates at 450 days. All tests were 2-sided with a signiﬁ-
cance value of p < 0.05. Analyses were performed with Stata
version 9.2 (Stata Corp., College Station, Texas).
Results
Of the 13,608 patients enrolled in the TRITON–TIMI
38 trial, 9,580 (70.4%) were recorded to be takingStudy Group has an independent copy of the trial database and conducted the current
analysis.
Manuscript received April 29, 2013; accepted June 21, 2013.
Table 1. Baseline Characteristics Stratiﬁed by Use of a CYP3A4-Metabolized Statin or CCB
CCB at
Randomization
(n ¼ 1,972)
No CCB at
Randomization
(n ¼ 11,636) p Value
Statin at
Randomization
(n ¼ 9,580)
No Statin at
Randomization
(n ¼ 4,028) p Value
Age 75 yrs 19.2 12.3 <0.001 12.2 16.0 <0.001
Male 70.7 74.7 <0.001 74.8 72.5 <0.001
White race 91.4 92.7 0.054 91.9 94.0 <0.001
Region <0.001 <0.001
North America 40.9 30.1 30.6 34.2
South America 2.4 4.2 4.4 2.8
Western Europe 20.8 27.0 24.7 29.6
Eastern Europe 15.2 26.0 24.7 23.7
Rest of the World 20.7 12.7 15.7 9.7
BMI, kg/m2 28.7 (25.7–32.2) 27.7 (25.1–30.9) <0.001 27.8 (25.2–31.2) 27.6 (24.9–30.8) <0.001
Current tobacco use 30.8 39.4 <0.001 38.4 37.6 0.38
Hypertension 82.4 61.2 <0.001 64.6 63.3 0.15
Hypercholesterolemia 64.6 54.2 <0.001 59.1 47.6 <0.001
Diabetes mellitus 31.5 21.7 <0.001 24.1 20.7 <0.001
Peptic ulcer disease 6.3 5.9 0.48 6.2 5.5 0.11
Carotid or vertebral arterial disease 4.7 2.6 <0.001 2.8 3.1 0.36
History stroke or TIA 6.2 3.4 <0.001 3.8 3.9 0.65
History of peripheral arterial disease 8.8 4.6 <0.001 5.4 4.9 0.32
Prior MI 23.9 16.9 <0.001 19.1 15.0 <0.001
Prior CABG 12.2 6.9 <0.0001 8.2 6.3 <0.001
Creatinine clearance <60 ml/min/m2 15.2 10.4 <0.001 10.3 13.2 <0.001
Index diagnosis of NSTEMI or UA 85.2 72.1 <0.001 75.2 71.2 <0.001
ACEI/ARB at randomization 68.3 54.1 <0.001 60.8 45.0 <0.001
Beta-blocker at randomization 70.7 74.5 <0.001 77.5 65.5 <0.001
Aspirin at randomization 97.3 96.6 0.12 97.6 94.6 <0.001
Randomized to prasugrel 51.0 49.9 0.36 50.0 50.3 0.70
Values are % or median (interquartile range).
ACEI ¼ angiotensin-converting enzyme inhibitor; ARB ¼ angiotensin receptor blocker; BMI ¼ body mass index; CABG ¼ coronary artery bypass graft
surgery; CCB ¼ calcium-channel blocker; MI ¼ myocardial infarction; NSTEMI ¼ non–ST-segment elevation myocardial infarction; PCI ¼ percutaneous
coronary intervention; TIA ¼ transient ischemic attack; UA ¼ unstable angina.
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1277a CYP3A4-metabolized statin, and 1,972 (14.5%) were
recorded to be taking a CCB at the time of randomization.
The baseline characteristics for patients who were or were not
taking statins or CCBs are shown in Table 1. The frequency
of use of the different types of CYP3A4-metabolized statins
and CCBs is included in Online Tables 1 and 2.
Patients on aCYP3A4-metabolized statin weremore likely
to be younger, male, and have an index diagnosis of a non–
ST-segment elevation ACS compared with patients not on
a statin (Table 1). Subjects treated with a statin were more
likely to have a history of hyperlipidemia, diabetes mellitus,
and prior MI or coronary artery bypass graft surgery, but were
less likely to have a reduced creatinine clearance (Table 1).
Patients treated with a CCB were more likely to be older,
female, and have additional risk factors including hyper-
tension, hyperlipidemia, diabetes, prior MI, family history of
CAD, cerebrovascular disease, peripheral arterial disease,
and congestive heart failure.
Statins and clinical outcomes. For patients randomized to
clopidogrel, the Kaplan-Meier rate of the primary endpointthrough long-term follow-up was similar for patients who
were (11.9%) or were not (12.4%) on a CYP3A4-metabo-
lized statin (unadjusted hazard ratio [HR]: 0.94; 95%
conﬁdence interval [CI]: 0.81 to 1.10; p ¼ 0.43) (Fig. 1).
After multivariable adjustment including the propensity to
be treated with a statin, there remained no signiﬁcant
association between statin use and the risk of CV death, MI,
or stroke for patients on clopidogrel (adjusted HR: 1.02;
95% CI: 0.85 to 1.22; p ¼ 0.83) (Table 2). Similarly, statin
use was also not associated with an increased risk of CV
death or MI (adjusted HR: 1.02; 95% CI: 0.85 to 1.23;
p ¼ 0.84) (Table 2).
Because patients could start or stop a statin during the
course of follow-up, we examined those clopidogrel-treated
patients who were recorded to be consistently taking
a CYP3A4-metabolized statin both at randomization and at
the end of the study (n ¼ 3,841, 56.5%). The consistent use
of statins was not associated with an increased risk of CV
death, MI, or stroke (adjusted HR: 0.96; 95% CI: 0.74 to
1.25; p ¼ 0.78) or CV death or MI (adjusted HR: 0.95; 95%
Figure 1. Risk of CV Events for Clopidogrel-Treated Patients With or
Without a Statin
Unadjusted Kaplan-Meier curves for risk of cardiovascular (CV) death,
myocardial infarction (MI), or stroke for clopidogrel-treated patients who were
(blue line) or were not (red line) on a CYP3A4-metabolized statin at
randomization. The risk of CV events was similar for clopidogrel-treated
patients regardless of background use of a statin.
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1278CI: 0.72 to 1.24; p ¼ 0.70), as compared with those patients
not consistently on a statin.
As a sensitivity analysis, we examined the association
between the use of atorvastatin and the risk of CV events for
patients on clopidogrel, because some studies have only
shown a pharmacodynamic interaction with clopidogrel for
this particular statin type. When atorvastatin was examined
individually, its use was also not associated with an increased
risk of CV death or MI (HR: 1.07; 95% CI: 0.92 to 1.25;
p ¼ 0.39) or stent thrombosis (HR: 0.99; 95% CI: 0.69 to
1.40; p ¼ 0.93) in clopidogrel-treated patients.
The efﬁcacy of prasugrel versus clopidogrel was similar for
patients who were (HR: 0.79; 95% CI: 0.70 to 0.90) or were
not (HR: 0.86; 95% CI: 0.72 to 1.04) on a statin (p for
interaction ¼ 0.43) (Fig. 2). Prasugrel signiﬁcantly reduced
the risk of stent thrombosis by 48% to 60% for patients who
were (HR: 0.52; 95%CI: 0.37 to 0.74) or were not (HR: 0.40;
95% CI: 0.24 to 0.66) on a statin (p for interaction ¼ 0.39).
CCBs and clinical outcomes. Before multivariable adjustment,
patients on a CCB had a higher risk of CV death, MI, or
stroke through long-term follow-up, regardless of whether
they were on clopidogrel or prasugrel. For patients randomized
to clopidogrel, the rate of the primary endpoint throughout
long-term follow-up was 15.7% for patients on a CCB versus
11.5% for those not a CCB (unadjusted HR: 1.38; 95% CI:
1.15 to 1.65; p ¼ 0.001). However, after adjusting for baseline
differences and the propensity to treat with a CCB, use of
a CCB was no longer associated with an increased risk of CV
death, MI, or stroke in clopidogrel-treated patients (adjustedHR: 1.16; 95% CI: 0.94 to 1.43; p ¼ 0.18) or CV death or
MI (adjusted HR: 1.17; 95% CI: 0.93 to 1.45; p ¼ 0.17)
(Table 2).
For those clopidogrel-treated patients who were recorded
to be taking a CCB both at the start and end of the study
(n ¼ 582, 10.5%), the consistent use of CCBs was not
associated with an increased risk of CV death, MI, or stroke
(adjusted HR: 1.06; 95% CI: 0.80 to 1.40; p ¼ 0.71) or CV
death or MI (adjusted HR: 1.02; 95% CI: 0.77 to 1.37;
p ¼ 0.87).
Patients on a CCB had a comparable reduction in CV
death, MI, or stroke with prasugrel versus clopidogrel (HR:
0.87; 95% CI: 0.68 to 1.10), as compared with those patients
not on a CCB (HR: 0.80; 95% CI: 0.71 to 0.90, p for
interaction ¼ 0.55) (Fig. 2). Prasugrel also signiﬁcantly
reduced the risk of stent thrombosis for patients who were
(HR: 0.30; 95% CI: 0.16 to 0.58) or were not (HR: 0.53;
95% CI: 0.39 to 0.74) on a CCB (p for interaction ¼ 0.13).
Concomitant use of multiple CYP450-metabolized medications.
In the event that a clinical threshold effect may exist for the
pharmacodynamic effects of clopidogrel, we examined CV
risk in those patients who were treated simultaneously with 2
or more medications that have been hypothesized to interfere
with the conversion of clopidogrel to its active metabolite. In
clopidogrel-treated patients, 694 individuals were simulta-
neously on a CYP3A4-metabolized statin and a CCB at
randomization. Within this group of patients on 2 CYP3A4-
metabolized medications, there remained no signiﬁcant
association between combined drug use and the risk of CV
death, MI, or stroke (adjusted HR: 1.19; 95% CI: 0.93 to
1.51), as compared with those patients not on either a statin
or CCB. Similarly, there was not an increased risk of CV
death, MI, or stroke for those patients simultaneously on
atorvastatin 80 mg daily and a CCB (adjusted HR: 0.82; 95%
CI: 0.37 to 1.84).
Only 236 clopidogrel-treated subjects were on a combi-
nation of a CCB, statin, and a proton pump inhibitor
at randomization. Within this group of subjects, the
concomitant use of 3 drugs that could interfere with the
hepatic metabolism of clopidogrel was not associated with an
increased risk of CV death, MI, or stroke (adjusted HR:
1.04; 95% CI: 0.70 to 1.54) when compared with patients
on none of these medications.Discussion
In a large population of patients with ACS, we found that the
use of statins, CCBs, or a combination of both these medi-
cations did not appear to interfere with the clinical efﬁcacy
of clopidogrel. These ﬁndings are clinically relevant in light
of prior pharmacodynamic studies that have shown con-
ﬂicting results as to whether statins or CCBs may attenuate
the acute antiplatelet effects of clopidogrel (1–6). Therefore,
Table 2. Kaplan-Meier Event Rates Through Long-Term Follow-Up Stratiﬁed by the Use of a Statin or CCB at Randomization for Patients
Treated With Clopidogrel
Statin
Adjusted HR
(95% CI)
Treated vs. Nontreated*
CCB
Adjusted HR
(95% CI)
Treated vs. NontreatedTreated Not Treated Treated Not Treated
CV death, MI, or stroke 11.9% (542/4,794) 12.4% (239/2,001) 1.02 (0.85–1.22) 15.7% (142/966) 11.5% (639/5,829) 1.16 (0.94–1.43)
CV death or MI 11.0% (503/4,794) 11.7% (225/2,001) 1.02 (0.85–1.23) 14.4% (131/966) 10.7% (597/5,829) 1.17 (0.93–1.45)
Values are % (n/N). Adjusted hazard ratios (HRs) (95% conﬁdence intervals [CI]) reﬂect the association between subjects treated with a CYP3A4-metabolized statin or calcium-channel blocker (CCB) use (as
compared with those subjects not treated with a CYP3A4-metabolized statin or CCB) and the risk of clinical outcomes after adjusting for potential confounders and the propensity to treat with the drug.
CV ¼ cardiovascular; MI ¼ myocardial infarction.
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1279this information provides important reassurance to clinicians
that these classes of drugs can be safely combined.
Both clopidogrel and prasugrel are pro-drugs that require
biotransformation via the CYP enzyme system to form their
active metabolites. Before undergoing hepatic metabolism,
85% of the clopidogrel pro-drug is converted to inactive
esterases and therefore unable to undergo hepatic metabo-
lism. By contrast, the metabolism of prasugrel appears to be
more efﬁcient because it involves a single CYP-dependent
step, and the pro-drug is not shunted down a dead-end
pathway (10). Although several CYP enzymes contribute to
the 2-step metabolism of clopidogrel, it has been suggested
that the greatest contribution is from the CYP3A4,
CYP3A5, and CYP2C19 isoenzymes (11). Supporting
the concept that CYP3A4 plays a key role in the conversion
of clopidogrel to its active metabolite, CYP3A4 enzyme
activity has been shown to be inversely correlated to the
pharmacodynamic response to clopidogrel (12). Although
the relative contribution of different CYP450 isoenzymes to
the metabolism of clopidogrel remains unclear, 1 in vitro
study using human microsomes containing CYP3A4 and
CYP3A5 suggested that these 2 isoenzymes are primarily
responsible for the conversion of clopidogrel to its active
metabolite (13). A second study demonstrated that the
CYP2C19 isoenzyme contributes substantially to bothFigure 2. Efﬁcacy of Prasugrel Versus Clopidogrel for Patients on a Statin or CC
The relative efﬁcacy of prasugrel versus clopidogrel for patients on a background of
(HRs) (95% conﬁdence interval [CI]) reﬂect the relative risk of CV death, MI, or stroke f
clopidogrel. Abbreviations as in Figure 1.bio-oxidative steps, whereas CYP3A4 is integral to the
second bio-oxidative step (11).
Lipophilic statins, including atorvastatin, simvastatin, and
lovastatin, aremetabolized byCYP3A4and therefore compete
with clopidogrel for its substrate. In ex vivo experiments, when
clopidogrel and atorvastatin were exposed in equimolar
amounts to human microsomes containing CYP3A4, clopi-
dogrel metabolism was inhibited by >90% (13). Further,
studies have shown that atorvastatin may attenuate the anti-
platelet effects of clopidogrel (1,2). These results were subse-
quently validated by a prospective randomized trial that
showed an interaction between atorvastatin and a 300-mg (but
not a 600-mg) loading dose of clopidogrel as assessed by light-
transmission aggregometry (3). By contrast, several studies
have since been unable to demonstrate a deﬁnitive interaction
between these classes of drugs (7). These discrepancies might
in part be explained by marked differences in study designs,
population size, clopidogrel dosing, platelet function
testing methodology, and concomitant medications (7). To
date, the clinical relevance of these ﬁndings has been
evaluated in several observational studies that have failed to
demonstrate that CYP3A4-metabolized statins interfere
with the clinical efﬁcacy of clopidogrel (14–19).
Because of their common requirement for CYP3A4
metabolism, there exists similar concern that CCBs mightB
CYP3A4-metabolized statins or calcium-channel blockers (CCBs). Hazard ratios
or patients treated with prasugrel as compared with those patients treated with
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1280interact with clopidogrel. This concern is supported by
several studies that have shown that CCBs attenuate the
antiplatelet effects of clopidogrel (4–6). However, as with
statins, some studies have failed to observe a pharmacody-
namic interaction between these classes of drugs (20,21). To
date, there exist limited data to determine whether use of
a CCB increases CV risk in clopidogrel-treated patients. In
a Danish registry of patients after MI, patients on a CCB
were observed to have an increased risk of CV events
regardless of whether or not they were treated with clopi-
dogrel, thereby suggesting the increase in risk was likely
explained by unidentiﬁed confounders (22). More recently,
there was no evidence of an interaction between clopidogrel
and CCB use in a post hoc analysis of 2,116 subjects in
a randomized trial of 2 dosage regimens of clopidogrel post-
PCI (23) or in 1,608 subjects after placement of a drug-
eluting stent (21).
In the current analysis of 13,608 subjects with ACS, we
did not ﬁnd that CYP3A4-metabolized statins, CCBs, or
concomitant use of both medications attenuated the clinical
efﬁcacy of clopidogrel. Moreover, the combination of
a proton pump inhibitor with 2 CYP3A4-metabolized drugs
also did not demonstrate an increased risk of CV events.
These data represent one of the largest study populations to
address the question of a possible drug–drug interaction
between these classes of drugs. Because the study population
was drawn from a clinical trial database, we were able to
carefully adjust for baseline differences and the propensity to
treat with either a statin or CCB. Although patients on
a CCB were found to be at increased risk of CV events, this
excess in CV risk did not persist after multivariable adjust-
ment in clopidogrel-treated patients; thereby highlighting
that CCB use was associated with a higher-risk patient
population rather than interfering with the efﬁcacy of clo-
pidogrel. Further, the relative efﬁcacy of prasugrel versus
clopidogrel was similar regardless of background use of
statins or CCBs, again suggesting that the clinical efﬁcacy of
clopidogrel was not attenuated in patients prescribed
CYP3A4-metabolized drugs.
Therefore, despite the previously reported in vitro inter-
action that was observed in some studies between clopi-
dogrel and CYP3A4-metabolized statins or CCBs, we did
not observe concomitant use of these classes of drugs to be
associated with an increased risk of CV events. These
ﬁndings highlight that there is still more to learn regarding
the relationship between platelet reactivity and clinical
outcomes. Further, an ex vivo measure of platelet function
may not reliably reﬂect the in vivo complexity of thrombosis,
inﬂammation, and endothelial function. Although a phar-
macodynamic interaction has been reported for some types
of proton pump inhibitors when combined with clopidogrel
(7), several outcome studies, including an analysis from the
TRITON–TIMI 38 trial, did not conﬁrm an increase in CV
events when these drug classes are combined (24,25). Ifa pharmacodynamic interaction indeed exists between clo-
pidogrel and CCBs or statins, it is plausible that this
interaction is too weak to translate into CV harm (26).
However, we still observed no signal toward increased risk
when multiple drugs that interfere with the CYP450 enzyme
system were combined.
Study limitations. Limitations to the current analysis include
the fact that use of statins and CCBs were not randomized,
thereby increasing the risk of confounding by indication or
by other unassessed variables, and therefore, causality cannot
be deﬁnitively determined. However, we performed exten-
sive multivariable adjustment for baseline differences and
included a propensity score to be treated with a statin or
CCB in our models. The use of concomitant medications
was captured at randomization and may have changed
because statins and CCBs could have been started or stopped
during the course of the trial. Because DNA samples were
only available in a subset of the TRITON–TIMI 38 pop-
ulation, our study was insufﬁciently powered to determine
whether an interaction might exist between CYP3A4-
metabolized medications and carriers of a reduced-function
CYP2C19 allele. Although loss-of-function variants in the
CYP3A4 gene exist, they are rare.
Conclusions
Overall, in patients with an ACS undergoing PCI, the
clinical efﬁcacy of clopidogrel did not appear to be signiﬁ-
cantly modiﬁed by concomitant CCB and/or statin use.
Further, the use of statins and CCBs did not inﬂuence the
relative efﬁcacy or safety of prasugrel as compared with
clopidogrel. Although only a randomized trial can deﬁni-
tively establish the clinical implications of combining statins
or CCBs with clopidogrel, the results of this study do not
support the need to avoid concomitant use of statins or
CCBs in patients receiving clopidogrel.
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